Atox1 may be a potential prognostic biomarker for estrogen-receptor (ER)-positive and early stages of breast cancers because increased expression levels of Atox1 correlated with poor survival for stages 1 and 2 breast cancers. Here, ESR1 is linked to breast carcinoma.